Although introduced into clinical medicine less than five years ago, sulfanilamide has received abundant clinical trial. In adequate dosage the drug has already been proved to be most valuable in the treatment of infections caused by many organisms, especially the gonococcus and the beta hemolytic streptococcus. Why is it then that in some cases of such infections its use results in failure? Are the failures due primarily to resistance of individual strains of bacteria or are they due to some abnormality in the individual patient? Why are there such wide variations in the curative effects of sulfanilamide in cases of similar infections, perhaps even of the same strain?
In an attempt to answer these questions, we have undertaken the task of reviewing our failures in a fairly extensive use of sulfanilamide in urologic practice. In this study we include of course only infections ordinarily responsive to sulfanilamide and patients able
BALLENGER EG, ELDER OF, McDONALD HP, COLEMAN RC. FAILURES IN THE TREATMENT OF URINARY TRACT INFECTIONS WITH SULFANILAMIDE. JAMA. 1939;112(16):1569–1571. doi:https://doi.org/10.1001/jama.1939.02800160033008
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: